Fortress Biotech Inc. Common Stock (FBIO)
Stock · NASDAQ · Health Care
$1.86as of 10/16/2026
Price chart
Active signals
FBIO Signal Track Record
How signals performed across all stocks →What FBIO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -3.2% | 36% | October 5, 2026 |
| Bollinger Band Breakout | 26 | -2.1% | 38% | July 9, 2026 |
| Bollinger Band Breakdown | 19 | -1.5% | 47% | September 28, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -2.3% | 50% | August 13, 2026 |
| Any 20-session window (baseline) | -2.2% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About FBIO
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne;…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 78
- Website
- www.fortressbiotech.com/
Fundamentals
- 1-day range
- $1.89$1.95
- Market cap
- $92.02M
- P/E (trailing)
- 0.58
- P/E (forward)
- -1.09
- EPS (trailing)
- $2.91
- Dividend yield
- —
- Beta
- 1.24
- Avg. volume
- 457.6K
How Fortress Biotech Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 31, 2026 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Fortress Biotech Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- FBIOFortress Biotech Inc. Common Stock$1.87▼ 2.09%Market cap $92.02MP/E 0.58$1.88$4.53
- VRCAVerrica Pharmaceuticals Inc. Common Stock$3.6▼ 4.89%Market cap $92.08MP/E —$3.28$9.82
- NTHINeOnc Technologies Holdings Inc. Common Stock$2.7▼ 1.82%Market cap $90.77MP/E —$2.5$12
- BMEABiomea Fusion Inc. Common Stock$0.869▲ 3.95%Market cap $90.37MP/E —$0.800501$2.24
- HRTXHeron Therapeutics Inc. Common Stock$0.36▼ 5.26%Market cap $94.45MP/E —$0.261$1.58
- ONCYOncolytics Biotech Inc. Common Stock$0.5▼ 9.09%Market cap $95.55MP/E —$1.48$4.49
- ALDXAldeyra Therapeutics Inc. Common Stock$0.7▼ 5.02%Market cap $95.91MP/E —$0.8619$5.93
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FBIO Fortress Biotech Inc. Common Stock | $92.02M | 0.58 | $1.87 | ▼ 2.09% | $1.88$4.53 |
| VRCA Verrica Pharmaceuticals Inc. Common Stock | $92.08M | — | $3.6 | ▼ 4.89% | $3.28$9.82 |
| NTHI NeOnc Technologies Holdings Inc. Common Stock | $90.77M | — | $2.7 | ▼ 1.82% | $2.5$12 |
| BMEA Biomea Fusion Inc. Common Stock | $90.37M | — | $0.869 | ▲ 3.95% | $0.800501$2.24 |
| HRTX Heron Therapeutics Inc. Common Stock | $94.45M | — | $0.36 | ▼ 5.26% | $0.261$1.58 |
| ONCY Oncolytics Biotech Inc. Common Stock | $95.55M | — | $0.5 | ▼ 9.09% | $1.48$4.49 |
| ALDX Aldeyra Therapeutics Inc. Common Stock | $95.91M | — | $0.7 | ▼ 5.02% | $0.8619$5.93 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →Institutional Ownership
March 31, 2026
- Total shares held
- 5.57M
- Total value held
- $13.84M
- Institutional holders
- 49
- Unknown1.04M
- Unknown966.0K
- Unknown506.6K
- Unknown305.5K
- Unknown290.3K
- Unknown254.1K
- Unknown230.1K
- Unknown209.4K
- Unknown197.1K
- Unknown196.8K
See the full, filterable feed with live charts on the MarketWall dashboard.